April 6, 2022

Company Name: Representative:

HEALIOS K.K.

Hardy TS Kagimoto, Chairman & CEO (TSE Growth Code: 4593)

Business Briefing for Institutional Investors

HEALIOS K.K. held a webinar to present an update on its business to institutional investors in Japan. The meeting agenda is provided below, and the presentation materials are available for viewing.

HEALIOS K.K. Business Briefing for Institutional Investors

Date and Time: Tuesday April 5, 2022, 10:00-12:00

Description:

1.

Introduction

Chairman and CEO

Hardy TS Kagimoto, MD

2.

Overview and Current Status of

Executive Vice President CMO (Chief

HLCM051 Clinical Trials

Medical Officer)

Masanori Sawada, MD, PhD, MBA

3.

iPSC Regenerative Medicine

Executive Officer Research field

eNK cells & UDC

Kouichi Tamura, Ph.D

Briefing materials: attachedContact: Department of Corporate Communications, HEALIOS K.K.

E-mail:ir@healios.jp

1

Company

HEALIOS K.K.

Date

April 5, 2022

Overview and Current Status of

HLCM051 Clinical Trials

Executive Vice President CMO (Chief Medical Officer) Masanori Sawada, MD, PhD, MBA

HLCM051 ARDS: Target Disease

Acute Respiratory Distress Syndrome or ARDS is a collective term for respiratory failure that occurs suddenly in critically ill patients (mainly due to severe pneumonia, sepsis, trauma, etc.). Activated inflammatory cells run amok and attack the lungs.

It is a disorder with a very high mortality rate (30 ~ 58%) and a poor prognosis, for which there is a need for novel therapies that can improve patient outcomes.

At present, there are no therapeutic drugs that can make a direct improvement to a patient's vital prognosis when ARDS develops. The only symptomatic treatment for respiratory failure includes artificial respiration.

Time-dependent change in CT image in ARDS affected lung

（出所） Ichikado K BMJ Open. 2012 Mar 1;2(2):e000545

ECMO

Artificial Respiration

HLCM051 ARDS: Overview of Cell Therapy

The allogeneic bone marrow-derived Multipotent Adult Progenitor Cell product (HLCM051) is expected to restore damaged lung tissue and improve respiratory function by reducing inflammation, regulating immune function, promoting angiogenesis, and protecting and repairing damaged cells and tissues.

Head

Cleveland, Ohio (U.S.A.)

Office

NASDAQ：ATHX

Developed

Stem cell product:

Products

MultiStem® （proprietary）

(Source) Based on materials provided by Athersys

3

HLCM051 ARDS: Multiple Mechanisms of Action

(Source) Athersys

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Healios KK published this content on 06 April 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 06 April 2022 03:41:04 UTC.